Tempest Therapeutics Inc.

11/12/2021 | Press release | Distributed by Public on 11/12/2021 06:08

Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer